GlassScriptPhysician profile
Rhonda L Pinkerman
NPI 1508940610
$2,550.52
in general payments reported to CMS, 2019-2025
15 companies · $615 in 2025
The $615 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $279 · 2023: $469 · 2024: $773 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $434.02 | 2021-2025 | Breztri, Airsupra |
| Abbott Laboratories | $286.49 | 2024 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Abbvie INC. | $220.29 | 2021-2024 | |
| Corcept Therapeutics | $214.70 | 2023-2024 | Korlym |
| Inspire Medical Systems, INC. | $168.01 | 2022 | |
| Amgen INC. | $145.61 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $135.91 | 2024 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $133.36 | 2025 | |
| Evoke Pharma, INC. | $125.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $121.76 | 2023 | Abilify Maintena, Abilify Asimtufii |
| Mylan Specialty L.P. | $120.50 | 2023 | Yupelri |
| Novo Nordisk INC | $120.05 | 2021 | |
| Akcea Therapeutics, INC. | $116.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.56 | 2022 | |
| Dynavax Technologies Corporation | $97.76 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Pinkerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.